PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
0.7571
+0.0017 (0.23%)
At close: Nov 24, 2025, 4:00 PM EST
0.7571
0.00 (0.00%)
Pre-market: Nov 25, 2025, 5:38 AM EST
PDS Biotechnology Employees
PDS Biotechnology had 24 employees as of December 31, 2024. The number of employees decreased by 1 or -4.00% compared to the previous year.
Employees
24
Change (1Y)
-1
Growth (1Y)
-4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,453,539
Market Cap
41.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24 | -1 | -4.00% |
| Dec 31, 2023 | 25 | -1 | -3.85% |
| Dec 31, 2022 | 26 | 4 | 18.18% |
| Dec 31, 2021 | 22 | 7 | 46.67% |
| Dec 31, 2020 | 15 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PDSB News
- 11 days ago - PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update - GlobeNewsWire
- 13 days ago - PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering - GlobeNewsWire
- 14 days ago - PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025 - GlobeNewsWire
- 18 days ago - PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results - GlobeNewsWire
- 25 days ago - New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 26 days ago - PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer - GlobeNewsWire
- 2 months ago - PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population - GlobeNewsWire